Glycine reuptake inhibition: A promising therapeutic strategy in the treatment of schizophrenia?

Future Medicinal Chemistry

Volumn 5, Issue 13, 2013, Pages 1475-1477

  Chue, Pierre S ^a   Baker, Glen B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

cognitive symptoms; glutamate; glycine receptor; glycine transporter; negative symptoms; NMDA receptor

Indexed keywords

ASENAPINE; BITOPERTIN; BREXPIPRAZOLE; CARIPRAZINE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; GLUTAMIC ACID; GLYCINE; GLYCINE RECEPTOR; GLYCINE TRANSPORTER 1; ILLICIT DRUG; KAINIC ACID RECEPTOR; LAMOTRIGINE; METABOTROPIC RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLANZAPINE; RISPERIDONE; SARCOSINE; SEROTONIN ANTAGONIST; TOPIRAMATE;

ANEMIA; CLINICAL STUDY; COGNITIVE DEFECT; COMPETITIVE INHIBITION; DIZZINESS; DOPAMINERGIC TRANSMISSION; ERYTHROCYTE; HUMAN; NEGATIVE SYNDROME; NEUROTRANSMISSION; NONHUMAN; POLYPHARMACY; POSITIVE SYNDROME; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROGNOSIS; RESPIRATION DEPRESSION; REVIEW; SCHIZOPHRENIA; SEIZURE;

ANIMALS; ANTIPSYCHOTIC AGENTS; GLYCINE; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; SCHIZOPHRENIA;

EID: 84884229725     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.118     Document Type: Review

References (20)

1. de Bartolomeis A, Sarappa C, Magara S, Iasevoli F. Targeting glutamate system for novel antipsychotic approaches: Relevance for residual psychotic symptom and treatment resistant schizophrenia. Eur. J. Pharmacol. 682(1-3), 1-11 (2012
2. Labrie V, Wong AH, Roder JC. Contributions of the d-serine pathway to schizophrenia. Neuropharmacology 62(3), 1484-1503 (2012
3. Papanastasiou E, Stone JM, Shergill S. When the drugs don't work: The potential of glutamatergic antipsychotics in schizophrenia. Br. J. Psychiatry.202, 91-3 (2013
4. Matsui T, Sekiguchi M, Hashimoto A, Tomita U, Nishikawa T, Wada K. Functional comparison of d-serine and glycine in rodents: The effect on cloned NMDA receptors and the extracellular concentration. J. Neurochem. 65(1), 454-458 (1995
5. Acton QA. Glutamate Receptors: Advances in Research and Application. Scholarly Editions, GA, USA (2011
6. Sendt KV, Giaroli G, Tracy DK. Beyond dopamine: Glutamate as a target for future antipsychotics. ISRN Pharmacol. 2012, 427267 (2012
7. Fell MJ, McKinzie DL, Monn JA, Svensson KA. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia. Neuropharmacology 62(3), 1473-1483(2012
8. Lin CH, Lane HY, Tsai GE. Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol. Biochem. Behav. 100(4), 665-677 (2012
9. Javitt DC. Glycine transport inhibitors in the treatment of schizophrenia. Handb. Exp. Pharmacol. 213, 367-399 (2012
10. Hashimoto K. Glycine transporter-1: A new potential therapeutic target for schizophrenia. Curr. Pharm. Des. 17(2), 112-20 (2011
11. Harsing LG, Zsilla G, Matyus P et al. Interactions between glycine transporter type 1 (GlyT-1) and some inhibitor molecules - glycine transporter type 1 and its inhibitors (review). Acta Physiol. Hung. 99(1), 1-17 (2012
12. Chue P. Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: Focus on the glycine transporter 1 (GlyT1). Curr. Pharm. Des. 19(7), 1311-20 (2013
13. Nunes EA, MacKenzie EM, Rossolatos D, Perez-Parada J, Baker GB, Dursun SM. d-serine and schizophrenia: An update. Expert Rev. Neurother. 12(7), 801-812 (2012
14. Bondi C, Matthews M, Moghaddam B. Glutamatergic animal models of schizophrenia. Curr. Pharm. Des. 18(12), 1593-1604 (2012
15. Tsai GE, Lin PY. Strategies to enhance N-methyl-d-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr. Pharm. Des. 16(5), 522-37 (2010
16. Choi YK, Gardner MP, Tarazi FI. Effects of risperidone on glutamate receptor subtypes in developing rat brain. Eur. Neuropsychopharmacol. 19(2), 77-84 (2009
17. Roenker NL, Gudelsky G, Ahlbrand R et al. Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801. Neurosci. Lett. 500(3), 167-171 (2011
18. Jardemark K, Marcus MM, Malmerfelt A, Shahid M, Svensson TH. Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission. Psychopharmacology (Berl.) 221(1), 115-131 (2012
19. Genius J, Giegling I, Benninghoff J, Rujescu D. Disturbed function of GABAergic interneurons in schizophrenia: Relevance for medical treatment? Curr. Pharm. Biotechnol. 13(8), 1549-1556 (2012
20. Kantrowitz J, Javitt DC. Glutamatergic transmission in schizophrenia: From basic research to clinical practice. Curr. Opin. Psychiatry 25(2), 96-102 (2012